Novo weathering the storm in Russia; Mylan and Gilead expand hep C licensing pact; NICE OKs Soliris;

> Novo Nordisk ($NVO) says it intends to stay in Russia for the "long haul" despite the country's ongoing economic downturn. Report

> Mylan ($MYL) is expanding its hep C licensing agreement with Gilead ($GILD) to include an investigational pan-genotypic prospect. Release

> The U.K.'s cost-effectiveness gatekeeper has approved Alexion's ($ALXN) Soliris in final guidance, making it the first med to pass through the watchdog's new assessment system for highly specialized technologies. Report

> GlaxoSmithKline ($GSK) has rolled out new respiratory treatments Arnuity Ellipta for asthma and Incruse Ellipta for COPD in the U.S. Release

> Purdue Pharma has launched Hysingla ER, a once-daily opioid with abuse-deterrent properties. Release

And Finally... Procter & Gamble's ($PG) ZzzQuil's Twitter feed came under fire last week for a tweet critics called sexist. More

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.